It’s a familiar song, the FDA singing high praise for Epidiolex, a pharmaceutical version of CBD that is less effective than the non-approved whole plant version and costs a ton more. Then there’s the matter of Epidiolex side-effects — everything from elevated liver enzymes and infections to attempts of suicide.
The entourage effect refers to hundreds of natural components within a plant interacting together to produce medicine with superior health benefits. Herbalists have recognized this forever … pharmaceuticals not so much.
Is the era of affordable, effective CBD oil coming to an end? Caught between CBD politics and Big Pharma’s backing of the Federal Drug Administration, the industrial hemp industry, as well as thousands of chronic disease sufferers, fear the worst with the likely approval of GW Pharmaceutical’s Epidiolex.
Behemoth seed company Monsanto denies its pending merger with Bayer has anything to do with a GMO marijuana monopoly. But rumored research labs in Uruguay and convenient patent connections suggests something evil is afoot.
DEA has taken yet another swipe at marijuana by amending its already bizarre classification of pot as a Schedule I drug. Now they’re trying to control the plant compound better known as CBD.